Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.

Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age3-18
SponsorSt. Justine's Hospital

About this trial

The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).

Eligibility criteria

Qualifiers

Presence of respiratory symptoms (cough and/or dyspnea)

Presence of signs of pneumonia (tachypnea, abnormal breath sounds, crackles)

Presence of fever

Positive chest radiography as interpreted by the treating physician

Disqualifiers

Any danger signs associated with pneumonia (severe indrawing, shock or severe dehydration, empyema, important pleural effusion, pulmonary abcess or pneumatocoele)

History of anaphylactic or allergic reaction to penicillin or amoxicillin according to the treating physician.

History of a serious nonimmunoglobulin E-mediated reactions (eg, Stevens-Johnson syndrome or toxic epidermal necrolysis) attributed to amoxicilin.

Caregiver unable to provide consent (language barrier or lack of caregiver presence)

Trial design

Treatments tested in this trial

  • Amoxicillin

Treatment groups

1,370 Participants
are divided into 2 treatment groups

Sponsors and collaborators